Trial results

Evaluation of Lixisenatide Efficacy in Diabetes Mellitus Type 2 With Failure of Other GLP-1 Analog

NCT02767596 on ClinicalTrials.gov · last registry update 2017-04-07

Stopped early, having planned 2 participants. The sponsor logged completion for February 2017. Primary outcome, as filed: Change in hemoglobin A1c. lixisenatide is already approved in the US for type 2 diabetes, so this is asking a further question rather than establishing the drug works at all. The registry entry has been edited 1 time since then.

Status

TERMINATED

Phase

P4

Drug

lixisenatide

Soliqua, Adlyxin

Sponsor

Laniado Hospital

Sponsor type

Other

Enrollment

2

Started

2016-07-12

Primary completion

2017-02 actual

Observed history

Every change this record has made since we started watching it. ClinicalTrials.gov shows only the current value. When a field is edited the previous one is overwritten and nothing is published to say so, so this history exists only because someone was recording it at the time.

Primary outcome

Change in hemoglobin A1c

Conditions studied

Diabetes Mellitus Type 2

Every field above is taken directly from the registry record. See all detected changes across the class, or the lixisenatide page for this molecule’s full trial and approval history.